Cantor Fitzgerald has initiated coverage on Bioventus (BVS, Financial) with an "Overweight" rating, indicating a positive outlook for the company. The coverage was announced by analyst Ross Osborn on July 7, 2025.
The analyst has set a price target of $12.00 USD for Bioventus (BVS, Financial). This initiation of coverage does not have any prior ratings or price targets for comparison, as it marks the first estimate provided by Cantor Fitzgerald.
The initiation of coverage on Bioventus (BVS, Financial) by Cantor Fitzgerald suggests confidence in the company's potential growth and market performance. Investors are advised to consider this new analysis when evaluating their investment strategies regarding Bioventus (BVS).
Wall Street Analysts Forecast
Based on the one-year price targets offered by 2 analysts, the average target price for Bioventus Inc (BVS, Financial) is $15.00 with a high estimate of $15.00 and a low estimate of $15.00. The average target implies an upside of 119.94% from the current price of $6.82. More detailed estimate data can be found on the Bioventus Inc (BVS) Forecast page.
Based on the consensus recommendation from 3 brokerage firms, Bioventus Inc's (BVS, Financial) average brokerage recommendation is currently 2.3, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Bioventus Inc (BVS, Financial) in one year is $5.90, suggesting a downside of 13.49% from the current price of $6.82. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Bioventus Inc (BVS) Summary page.
